Ocular Therapeutix (OCUL) Q4 2024 earnings summary

Executive summary

• 2024 marked a transformational year with a sharpened focus on redefining retina care, prioritizing the disruption of Wet AMD treatment through AXPAXLI and expanding into NPDR and DME.

• Key clinical trial updates for AXPAXLI in wet AMD aim to accelerate NDA submission and support a 6-12 month dosing label.

• Early clinical results in NPDR and DME show significant expansion opportunities.

• Several updates were announced to enhance and accelerate the AXPAXLI registrational program, including protocol amendments and trial optimizations.

• Cash balance of $392.1M as of December 31, 2024, expected to fund operations into 2028 with no plans to raise additional capital in 2025.

Financial highlights

• Q4 2024 net revenue was $17.1M, up 15.4% from $14.8M in Q4 2023; full year 2024 net revenue was $63.7M, up 9.0% from $58.4M in 2023.

• Q4 2024 net loss was $(48.4)M, or $(0.29) per share, compared to $(29.2)M, or $(0.35) per share, in Q4 2023.

• Full year 2024 net loss was $(193.5)M, or $(1.22) per share, versus $(80.7)M, or $(1.01) per share, in 2023.

• R&D expenses rose to $41.0M in Q4 2024 (from $16.2M in Q4 2023) and $127.6M for 2024 (from $61.1M in 2023), reflecting increased clinical trial activity.

• Cash and cash equivalents totaled $392.1M at year-end 2024.

Outlook and guidance

• Cash runway projected into 2028, with no intention to raise additional capital in 2025.

• Top-line data for SOL-1 expected in Q1 2026 due to protocol amendments and masking requirements.

• NDA submission planned after SOLAR's 56-week primary endpoint is reached.

• Awaiting FDA feedback on NPDR and DME trial designs in the first half of 2025.